Evidence map›Paper›PMID 38257338›Full record

ArticleMolecules (Basel, Switzerland)2024

Synthesis of [

Sangram Nag, Kevin Jia, Ryosuke Arakawa, Prodip Datta, Daniel Scott, Christopher Shaffer, Mohammad Mahdi Moein, Matthew Hutchison, Maciej Kaliszczak, Christer Halldin

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Recent advances in [Nuclear medicine and biology · 2026
    Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Sangram NagDepartment of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, 171 64 Stockholm, Sweden.ORCID 0000-0003-3590-4256
Kevin JiaDepartment of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, 171 64 Stockholm, Sweden.
Ryosuke ArakawaDepartment of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, 171 64 Stockholm, Sweden.
Prodip DattaDepartment of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, 171 64 Stockholm, Sweden.
Daniel ScottBIOGEN MA Inc., 225 Binney St., Cambridge, MA 02142, USA.
Christopher ShafferBIOGEN MA Inc., 225 Binney St., Cambridge, MA 02142, USA.
Mohammad Mahdi MoeinDepartment of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, 171 64 Stockholm, Sweden.ORCID 0009-0000-8379-6101
Matthew HutchisonBIOGEN MA Inc., 225 Binney St., Cambridge, MA 02142, USA.
Maciej KaliszczakBIOGEN MA Inc., 225 Binney St., Cambridge, MA 02142, USA.
Christer HalldinDepartment of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, 171 64 Stockholm, Sweden.
Stockholm County Council · SEBiogen (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to measure the brain penetrance and kinetics of BIIB104, a first-in-class AMPA receptor potentiator developed for cognitive impairment associated with schizophrenia. It was recently halted in phase 2 clinical development, and there are a lack of tools to directly measure AMPA receptor engagement. To achieve this, the drug candidate was radiolabeled with carbon-11, and its brain penetrance and kinetics were measured in non-human primates via dynamic PET scans. Radiolabeling was achieved through a three-step nucleophilic [

Indexed as

Positron-Emission TomographyReceptors, AMPAalpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic AcidAnimalsBrainPrimatesalpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic AcidReceptors, AMPAAMPAbio-distributionnon-human primatePETradiosynthesis

Identifiers

PMID38257338
PMCPMC10818776
OpenAlexW4390885882

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.